Analysts Offer Insights on Healthcare Companies: Horizon Pharma Inc (HZNP) and Akebia Therapeutics (AKBA)


Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Horizon Pharma Inc (NASDAQ:HZNP) and Akebia Therapeutics (NASDAQ:AKBA).

Horizon Pharma Inc (HZNP)

In a report released today, Gary Nachman from BMO Capital reiterated a Hold rating on Horizon Pharma Inc, with a price target of $19. The company’s shares closed yesterday at $20.12, close to its 52-week high of $20.25.

According to TipRanks.com, Nachman is a 4-star analyst with an average return of 11.4% and a 55.6% success rate. Nachman covers the Healthcare sector, focusing on stocks such as Sienna Biopharmaceuticals Inc, Bausch Health Companies Inc, and Pacira Pharmaceuticals.

Currently, the analyst consensus on Horizon Pharma Inc is a Moderate Buy with an average price target of $21.60.

See today’s analyst top recommended stocks >>

Akebia Therapeutics (AKBA)

Mizuho Securities analyst Difei Yang maintained a Buy rating on Akebia Therapeutics today and set a price target of $21. The company’s shares closed yesterday at $9.72, close to its 52-week low of $7.90.

Yang said:

“We anticipate the closing of the merger between Akebia and Keryx Biopharmaceuticals (KERX, Not rated) will likely happen sometime by year-end 2018.”

According to TipRanks.com, Yang is a 5-star analyst with an average return of 22.7% and a 53.7% success rate. Yang covers the Healthcare sector, focusing on stocks such as Nightstar Therapeutics Limited, Alder Biopharmaceuticals, and Audentes Therapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Akebia Therapeutics with a $21.25 average price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts